HCA Healthcare, Inc.

Valuation Analysis

About the Company

HCA Healthcare, Inc. en bref

HCA Healthcare, Inc. (HCA) is currently trading at 326,91 € with a market capitalization of 72,5 Md €. The trailing P/E ratio stands at 12.92x, with a forward P/E of 11.33x. The 52-week range spans from 287,68 € to 485,15 €; the current price is 32.6% below the yearly high. Year-over-year revenue growth stands at +4.3%. The net profit margin stands at 8.89%.

💰 Dividende

HCA Healthcare, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

21 analystes évaluent HCA Healthcare, Inc. (HCA) au consensus : Acheter. L'objectif de cours moyen est de 438,99 €, soit un potentiel de +34.29% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 345,22 € à 553,57 €.

HCA Healthcare, Inc. : la thèse d'investissement en détail

HCA Healthcare, Inc. (HCA) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 34.29% upside from current levels — analyst sentiment is firmly constructive. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

Revenue growth has slowed to just 4.3%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

Valorisation en contexte

The PEG ratio at 1.2 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 9x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 11.33x is meaningfully below the trailing 12.92x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 34.29% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy HCA Healthcare, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.